Free Writing Prospectus dated December 1, 2020
Filed pursuant to Rule 433
Relating to the Preliminary Prospectus Supplement dated December 1, 2020
Registration Statement No. 333-228656
Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering
NEWTON, Mass., December 1, 2020 Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical
company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney
disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of the Company, at
a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
The Company also has granted to the underwriter a 30-day option to purchase up to an additional 1,200,000
shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Allena, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the
underwriters option to purchase additional common stock, are expected to be approximately $10.0 million. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes.
The shares of common stock are being offered by the Company pursuant to a shelf registration statement on Form
S-3 (File No. 333-228656) previously filed with the Securities and Exchange Commission (the SEC) on December 3, 2018, and declared effective by the
SEC on December 26, 2018. The offering of the shares of common stock is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and
accompanying prospectus relating to, the and describing the terms of, the offering will be filed with the SEC and will be available on the SECs website at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement
and accompanying prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an
offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allenas lead product candidate, reloxaliase, is currently being evaluated in a pivotal
Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney
disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1b multiple-ascending dose study and a Phase 2 proof-of-concept study planned for 2021.